Belluscura PLC The US Centers for Medicare & Medicaid Services
08 Julho 2021 - 3:00AM
RNS Non-Regulatory
TIDMBELL
Belluscura PLC
08 July 2021
Belluscura PLC
("Belluscura" or the "Company" or "Group")
The US Centers for Medicare & Medicaid Services
Proposed Broadening of Home Use of Oxygen to Treat Cluster
Headaches
The US Centers for Medicare & Medicaid Services (CMS) is
proposing changes to two separate, but medically related, National
Coverage Determinations (NCDs) relating to home oxygen therapy.
First, CMS proposes to remove its NCD at section 240.2.2 of the
Medicare NCD Manual, ending coverage with evidence development, and
allow the Medicare Administrative Contractors (MACs) to make
coverage determinations regarding the use of home oxygen and oxygen
equipment for Cluster Headaches (CH).
CMS also proposes to modify its NCD for Home Use of Oxygen at
section 240.2 of the Medicare NCD Manual to expand patient access
to oxygen and oxygen equipment in the home, and to permit
contractors to cover the use of home oxygen and oxygen equipment in
order to treat CH and other acute conditions.
Currently Section 240.2, effective since October 27, 1993
provides for home oxygen therapy only if the patient is in the
chronic stable state. CMS has noted, "We note that since the
inception of the Public Health Emergency (PHE) due to the COVID 19
pandemic, CMS has begun to permit health care services to increase
the capacity of the American health care system outside the setting
of the traditional inpatient hospital, including the treatment of
acute illnesses."
CMS is seeking comments on its proposed decisions consistent
with the public process established by --1862(l) of the Social
Security Act.
Robert Rauker, Belluscura CEO commented: "If approved, this
gives another substantial opportunity for Belluscura, in particular
with the launch of its X-PLO(2) R DX Model in the first half of
2022. Shareholders will be kept fully updated on developments from
the CMS."
For further information please contact:
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive via Walbrook PR
Officer
Anthony Dyer, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
Relations)
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
558 258
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing
oxygen enrichment technology spanning broad industries and
therapies. Our innovative oxygen technologies are designed with a
global purpose: to create improved health and economic outcomes for
the patients, healthcare providers and insurance organisations.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKOBNPBKDQOK
(END) Dow Jones Newswires
July 08, 2021 02:00 ET (06:00 GMT)
Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Belluscura (LSE:BELL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024